AOP-Wiki

API

All KERs

Showing 1576 to 1600 of 3102 KERs

ID	Upstream Event	Downstream Event	Creation Date	Last Updated	AOPs

2858	2117: Increase, goblet cell number	962: Increase, Mucin production	Mar 15, 2023	Mar 17, 2023	1 AOP 148: EGFR Activation Leading to Decreased Lung Function
3212	2137: Increase, Gonadotropins concentration in plasma	1690: Decrease, circulating testosterone levels	May 8, 2024	May 8, 2024	None
3716	2137: Increase, Gonadotropins concentration in plasma	2402: Increased, E2 production in ovaries	Jan 29, 2026	Feb 3, 2026	3 AOPs 623: Activation, estrogen receptor alpha leads to persistent vaginal cornification via increased kisspeptin release 637: Activation, estrogen receptor alpha leads to increased uterine weight via earlier proliferation of cells of the uterine lining 639: Activation, estrogen receptor alpha leads to precocious puberty via increased kisspeptin release
3679	2383: Increase, Hemopericardium	947: Increase, Early Life Stage Mortality	Oct 30, 2025	Oct 30, 2025	3 AOPs 612: Peroxisome proliferator-activated receptor alpha activation leading to early life stage mortality via reduced adenosine triphosphate 613: Peroxisome proliferator-activated receptor alpha activation leading to early life stage mortality via increased reactive oxygen species production 614: Peroxisome proliferator-activated receptor alpha activation leading to early life stage mortality via reduced vascular endothelial growth factor
3742	2412: Increase, Hepatic intracellular active GC	122: Increase, GR activation	Feb 24, 2026	Feb 24, 2026	6 AOPs 624: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated mitochondrial dysfunction 625: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated oxidative stress 626: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated endoplasmic reticulum stress 627: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated mitochondrial dysfunction 628: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated oxidative stress 629: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated endoplasmic reticulum stress
295	265: Increase, HSC activation	68: Increase, Collagen accumulation	Nov 29, 2016	Dec 5, 2018	8 AOPs 38: Protein Alkylation leading to Liver Fibrosis 144: Endocytic lysosomal uptake leading to liver fibrosis 624: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated mitochondrial dysfunction 625: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated oxidative stress 626: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated endoplasmic reticulum stress 627: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated mitochondrial dysfunction 628: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated oxidative stress 629: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated endoplasmic reticulum stress
2892	265: Increase, HSC activation	1501: Increase, ECM deposition	Apr 13, 2023	Jan 30, 2025	1 AOP 494: AhR activation leading to liver fibrosis
3217	265: Increase, HSC activation	459: Increase, Liver steatosis	May 14, 2024	May 14, 2024	None
3725	2405: Increase, Hepatocellular lipotoxicity	177: Increase, Mitochondrial dysfunction	Feb 10, 2026	Feb 10, 2026	1 AOP 627: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated mitochondrial dysfunction
3736	2405: Increase, Hepatocellular lipotoxicity	1815: Increase, ER stress	Feb 11, 2026	Feb 11, 2026	2 AOPs 626: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated endoplasmic reticulum stress 629: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated endoplasmic reticulum stress
3745	2405: Increase, Hepatocellular lipotoxicity	1392: Increase, Oxidative Stress	Feb 24, 2026	Feb 24, 2026	2 AOPs 625: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated oxidative stress 628: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated oxidative stress
1994	1698: Increase, hypermethylation of the promotor region of GnRHR	1699: Decease, expression of GnRHR	Oct 30, 2019	Oct 30, 2019	1 AOP 310: Embryonic Activation of the AHR leading to Reproductive failure, via epigenetic down-regulation of GnRHR
743	740: Increase, Hyperplasia (follicular cells)	741: Increase, Adenomas/carcinomas (follicular cell)	Nov 29, 2016	Dec 3, 2016	3 AOPs 110: Inhibition of iodide pump activity leading to follicular cell adenomas and carcinomas (in rat and mouse) 119: Inhibition of thyroid peroxidase leading to follicular cell adenomas and carcinomas (in rat and mouse) 162: Enhanced hepatic clearance of thyroid hormones leading to thyroid follicular cell adenomas and carcinomas in the rat and mouse
783	782: Increase, Hyperplasia (forestomach epithelial cells)	779: Increase, Papillomas/carcinomas (squamous cells)	Nov 29, 2016	Dec 3, 2016	1 AOP 115: Epithelial cytotoxicity leading to forestomach tumors (in mouse and rat)
771	772: Increase, Hyperplasia (glandular epithelial cells of endometrium)	773: Increase, Endometrial adenocarcinomas	Nov 29, 2016	Dec 3, 2016	1 AOP 112: Increased dopaminergic activity leading to endometrial adenocarcinomas (in Wistar rat)
2972	772: Increase, Hyperplasia (glandular epithelial cells of endometrium)	1896: Genomic instability	Jul 27, 2023	Mar 27, 2025	1 AOP 503: Activation of uterine estrogen receptor-alfa leading to endometrial adenocarcinoma, via epigenetic modulation
3608	772: Increase, Hyperplasia (glandular epithelial cells of endometrium)	1070: Increased, adenosquamous carcinomas of endometrium	Aug 26, 2025	Sep 18, 2025	1 AOP 167: Early-life estrogen receptor agonism leading to endometrial adenosquamous carcinoma via promotion of sine oculis homeobox 1 progenitor cells
731	744: Increase, Hyperplasia (Leydig cells)	745: Increase, Leydig cell tumors	Nov 29, 2016	Dec 3, 2016	2 AOPs 111: Decrease in androgen receptor activity leading to Leydig cell tumors (in rat) 120: Inhibition of 5α-reductase leading to Leydig cell tumors (in rat)
761	767: Increase, Hyperplasia (renal tubular cells)	713: Increase, Adenomas/carcinomas (renal tubular)	Nov 29, 2016	Dec 3, 2016	1 AOP 105: Alpha2u-microglobulin cytotoxicity leading to renal tubular adenomas and carcinomas (in male rat)
728	735: Increase, Hyperplasia (terminal bronchiolar cells)	736: Increase, Adenomas/carcinomas (bronchioloalveolar)	Nov 29, 2016	Dec 3, 2016	1 AOP 109: Cytotoxicity leading to bronchioloalveolar adenomas and carcinomas (in mouse)
786	784: Increase, Hyperplasia (tubular epithelial cells)	713: Increase, Adenomas/carcinomas (renal tubular)	Nov 29, 2016	Dec 3, 2016	1 AOP 116: Cytotoxicity leading to renal tubular adenomas and carcinomas (in male rat)
798	796: Increase, Hyperplasia (urothelial)	797: Increase, Adenomas/carcinomas (urothelial)	Nov 29, 2016	Dec 3, 2016	1 AOP 121: Urinary bladder calculi leading to urothelial papillomas and carcinomas (in mouse and rat)
2085	796: Increase, Hyperplasia (urothelial)	1763: carcinogenicity	Apr 21, 2020	Apr 21, 2020	1 AOP 335: AOP for urothelial carcinogenesis due to chemical cytotoxicity by mitochondrial impairment
1581	1343: Increase, hypertension	1226: Respiratory irritability	Jun 23, 2017	Jun 23, 2017	None
742	739: Increase, Hypertrophy and proliferation (follicular cell)	740: Increase, Hyperplasia (follicular cells)	Nov 29, 2016	Dec 3, 2016	3 AOPs 110: Inhibition of iodide pump activity leading to follicular cell adenomas and carcinomas (in rat and mouse) 119: Inhibition of thyroid peroxidase leading to follicular cell adenomas and carcinomas (in rat and mouse) 162: Enhanced hepatic clearance of thyroid hormones leading to thyroid follicular cell adenomas and carcinomas in the rat and mouse

Key Event Relationships (KERs)

All KERs